Peptide from NSP7 is able to form amyloid-like fibrils: Artifact or challenge to drug design?

• We found potential amyloidogenic fragment in NSP7 SARS-CoV2 protein in silico; • NSP7 (52–62) fragment is able to form amyloid-like fibrils; • The possibility of using such a peptide as the basis for an antiviral drug is discussed.

Detalles Bibliográficos
Autores principales: Garmay, Yuri, Rubel, Aleksandr, Egorov, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2023
Materias:
BBA Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711895/
https://www.ncbi.nlm.nih.gov/pubmed/36462605
http://dx.doi.org/10.1016/j.bbapap.2022.140884
_version_ 1784841677793394688
author Garmay, Yuri
Rubel, Aleksandr
Egorov, Vladimir
author_facet Garmay, Yuri
Rubel, Aleksandr
Egorov, Vladimir
author_sort Garmay, Yuri
collection PubMed
description • We found potential amyloidogenic fragment in NSP7 SARS-CoV2 protein in silico; • NSP7 (52–62) fragment is able to form amyloid-like fibrils; • The possibility of using such a peptide as the basis for an antiviral drug is discussed.
format Online
Article
Text
id pubmed-9711895
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-97118952022-12-01 Peptide from NSP7 is able to form amyloid-like fibrils: Artifact or challenge to drug design? Garmay, Yuri Rubel, Aleksandr Egorov, Vladimir Biochim Biophys Acta Proteins Proteom BBA Research Letter • We found potential amyloidogenic fragment in NSP7 SARS-CoV2 protein in silico; • NSP7 (52–62) fragment is able to form amyloid-like fibrils; • The possibility of using such a peptide as the basis for an antiviral drug is discussed. Elsevier B.V. 2023-02-01 2022-12-01 /pmc/articles/PMC9711895/ /pubmed/36462605 http://dx.doi.org/10.1016/j.bbapap.2022.140884 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle BBA Research Letter
Garmay, Yuri
Rubel, Aleksandr
Egorov, Vladimir
Peptide from NSP7 is able to form amyloid-like fibrils: Artifact or challenge to drug design?
title Peptide from NSP7 is able to form amyloid-like fibrils: Artifact or challenge to drug design?
title_full Peptide from NSP7 is able to form amyloid-like fibrils: Artifact or challenge to drug design?
title_fullStr Peptide from NSP7 is able to form amyloid-like fibrils: Artifact or challenge to drug design?
title_full_unstemmed Peptide from NSP7 is able to form amyloid-like fibrils: Artifact or challenge to drug design?
title_short Peptide from NSP7 is able to form amyloid-like fibrils: Artifact or challenge to drug design?
title_sort peptide from nsp7 is able to form amyloid-like fibrils: artifact or challenge to drug design?
topic BBA Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711895/
https://www.ncbi.nlm.nih.gov/pubmed/36462605
http://dx.doi.org/10.1016/j.bbapap.2022.140884
work_keys_str_mv AT garmayyuri peptidefromnsp7isabletoformamyloidlikefibrilsartifactorchallengetodrugdesign
AT rubelaleksandr peptidefromnsp7isabletoformamyloidlikefibrilsartifactorchallengetodrugdesign
AT egorovvladimir peptidefromnsp7isabletoformamyloidlikefibrilsartifactorchallengetodrugdesign

Ejemplares similares